---
document_datetime: 2025-07-23 17:48:32
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/supemtek-tetra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: supemtek-tetra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3281788
conversion_datetime: 2025-12-21 16:15:30.349901
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Supemtek Tetra

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                  | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                     |
|-------------------------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 5 year / EMA/R/0000249010 | Renewal of marketing authorisation | 22/05/2025                          | 18/07/2025                                  | SmPC, Labelling and              | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Supemtek Tetra in the approved indication |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            | PL                               | remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000245320 | This was an application for a group of variations. A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted | 24/01/2025 | 28/03/2025 | SmPC, Annex II, Labelling and PL |                                                                                                                    |